Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against ADMA Biologics, Inc. Accessibility StatementSkip NavigationMILWAUKEE, March 25, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against ADMA (NASDAQ: ADMA). The investigation results from inaccurate statements ADMA may have made regarding its financial statements, business operations and prospects.Click hereto join our investigation or to obtain additional information, or contact us at [email protec ...

• ADMA Biologics stock is testing key support levels. What’s pressuring ADMA?Culper Research Describes ADMA Short; Alleges MisreportingThe report from Culper Research, released on Tuesday, alleges that ADMA Biologics has been misrepresenting its financial results and operating metrics.The firm disclosed that it holds a short position in ADMA, which adds a layer of skepticism to its claims.In response, ADMA Biologics emphasized its commitment to transparency and adherence to U.S. Securities and Exchange Com ...

Adma Biologics (ADMA) has been on a downward spiral lately with significant selling pressure. After declining 27% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum osc ...

RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today addressed a report issued on March 24, 2026 by Culper Research (the “Short Report”), a firm that has published similarly negative “research reports” regarding public companies after taking short positions in the stock. The Short Report d ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:EQT Corporation (EQT) : This oil and gas company has seen the Zacks Consensus Estimate for its current year earnings increasing 33.5% over the last 60 days.BCB Bancorp, Inc. (BCBP) : This bank holding company has seen the Zacks Consensus Estimate for its current year earnings increasing 14.1% over the last 60 days.Comfort Systems USA, Inc. (FIX) : This mechanical and electrical contracting company has seen the Zacks Consensus Estimate f ...

ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best NASDAQ stocks under $30 to buy. On March 2, ADMA Biologics announced a significant capital return initiative for 2026, targeting a total of ~$200 million in share repurchases. As a primary component of this plan, the company entered into a $125 million ASR (accelerated share repurchase) agreement with JPMorgan Chase Bank. This move is supported by the company’s strong financial standing and sustained free cash flow. Under the specific terms of the ASR, ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Lifetime Brands (LCUT) : This company which, is a leading designer, marketer and distributor of kitchenware, has seen the Zacks Consensus Estimate for its current year earnings increasing 35.6% over the last 60 day.Enerflex Ltd. (EFXT) : This company, which provides oilfield services for natural gas and petroleum producers, has seen the Zacks Consensus Estimate for its current year earnings increasing 19.5% over the last 60 days.Magna I ...

Company Performance - Adma Biologics (ADMA) stock closed at $15.02, reflecting a +1.01% change from the previous day's closing price, outperforming the S&P 500's daily loss of 0.28% [1] - The stock has decreased by 7% over the past month, contributing to a 7.53% loss in the Medical sector, which is greater than the S&P 500's loss of 3.59% [1] Earnings Forecast - The Zacks Consensus Estimates predict earnings of $0.96 per share and revenue of $639.74 million for the year, representing increases of +60% and +25.4% compared to the previous year [2] Analyst Estimates - Changes in analyst estimates for Adma Biologics are crucial as they reflect short-term business trends, with upward revisions indicating positive sentiment regarding the company's operations and profit generation [3] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with 1 rated stocks delivering an average annual return of +25% since 1988 [5] - Adma Biologics currently holds a Zacks Rank of 1 (Strong Buy), with the Zacks Consensus EPS estimate having increased by 12.35% over the past month [5] Valuation Metrics - Adma Biologics has a Forward P/E ratio of 15.57, which is lower than the industry's Forward P/E of 18.65, indicating a valuation discount [6] - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has a Zacks Industry Rank of 142, placing it in the bottom 43% of over 250 industries [6]

Core Insights - B Group Inc. increased its stake in ADMA Biologics by 4.1% in Q3, owning 2,412,542 shares, which constitutes 26.9% of its holdings, valued at approximately $35.37 million [2] - Several institutional investors have also increased their positions in ADMA Biologics, with Marathon Capital Management raising its stake by 64.5% and Comerica Bank by 821.9% during the same period [3] - ADMA Biologics reported a revenue of $139.16 million for the last quarter, reflecting an 18.4% year-over-year increase, with an EPS of $0.20, matching analysts' expectations [5] Institutional Holdings - Institutional investors own 75.68% of ADMA Biologics' stock, indicating strong institutional interest [3] - Notable increases in holdings include Marathon Capital Management (64.5% increase) and Comerica Bank (821.9% increase) [3] Price Performance - ADMA Biologics shares opened at $15.15, with a 12-month low of $13.76 and a high of $25.67 [4] - The company has a market capitalization of $3.61 billion and a price-to-earnings ratio of 25.25 [4] Analyst Ratings - Zacks Research upgraded ADMA Biologics from "hold" to "strong-buy," while Wall Street Zen upgraded it from "hold" to "buy" [6] - The consensus rating for ADMA Biologics is "Buy," with a target price of $32.00 [6] Insider Transactions - Director Steve Elms purchased 7,000 shares at an average cost of $15.67, increasing his position by 0.34% [7] - COO Kaitlin M. Kestenberg-Messina sold 10,096 shares at an average price of $15.63, decreasing her ownership by 2.12% [7] Company Overview - ADMA Biologics is a biopharmaceutical company focused on developing and commercializing specialty plasma-derived biologics for treating primary immunodeficiency and infectious diseases [8] - The company's product portfolio includes BIVIGAM, a human immunoglobulin intravenous therapy approved in the U.S. [9]

Industry Overview - The biotech industry has shown strong performance in 2026, driven by robust fourth-quarter results, new drug approvals, and progress in drug pipelines despite regulatory challenges and pricing pressures [1][12] - The sector is expected to continue attracting investor interest due to the ongoing demand for innovative medical treatments [1] Mergers and Acquisitions - A recent increase in M&A activity is supporting sector momentum, with large pharmaceutical and biotech companies expanding their portfolios through strategic collaborations and acquisitions [2][8] - Notable acquisitions include Johnson & Johnson's purchase of Halda Therapeutics for prostate cancer treatment and Novartis's acquisition of Avidity Biosciences for $12 billion to enhance its neuroscience pipeline [10][11] Company Performance - Biotech companies such as Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals, and Liquidia Corporation are positioned to outperform the sector [3] - Liquidia Corporation's Yutrepia generated sales of $148.3 million in 2025, with a strong growth trajectory expected [24][25] - ANI Pharmaceuticals reported a 75.6% increase in sales of its ACTH-based injection Cortrophin Gel, reaching $347.8 million in 2025 [27][28] - ADMA Biologics is experiencing strong growth driven by Asceniv, with expectations for revenue acceleration in 2026 [31][32] - Terns Pharmaceuticals is advancing its lead candidate TERN-701, with promising data presented at a recent meeting [34][35] Industry Trends - The focus on innovation and execution is critical, with significant investments in drug development and the use of AI technology in drug discovery [5][12] - Successful commercialization remains a challenge for smaller biotech firms, often leading to collaborations with larger companies [6][7] Market Performance - The Zacks Biomedical and Genetics industry has outperformed both the Zacks Medical sector and the S&P 500, gaining 18.8% over the last six months compared to 5.6% and 3.3% respectively [18] - The industry is currently trading at a trailing 12-month price-to-sales ratio of 2.40X, lower than the S&P 500's 5.63X [21]